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become an important issue in the therapeutic management of IC (6-10). 76
In vitro antifungal susceptibility testing is currently recommended to detect resistance in 77
Candida species and to guide antifungal treatment (6, 11) . Microdilution broth methods such 78 as EUCAST and CLSI are the reference methods for antifungal susceptibility testing. 79
Nevertheless, because these reference methods are labor intensive and time-consuming, most 80 clinical microbiology laboratories use commercial methods, such as the Etest®, for routine 81 determination of minimum inhibitory concentrations (MICs). It is therefore essential to 82 evaluate these commercial tests and to determine their ability to give MIC values that agree 83 with those from the reference methods. 84
With this aim, a prospective, multicenter French study was performed to compare the 85 EUCAST and Etest® methods for micafungin susceptibility testing of a large panel of clinical 86 isolates of different Candida species. Sixteen centers (six in Paris area and 10 across France) 87 participated in the study. Over a 2-month period, each center was asked to test 64 Candida 88 isolates, from any clinical sample, of the following species: 10 isolates of each of the six most 89 common pathogenic species (C. albicans, C. glabrata, C. tropicalis, C. parapsilosis, C. kefyr 90 and C. krusei) and four isolates belonging to other Candida species. Species identification 91 was performed in each center according to the currently recommended phenotypic methods 92 (12). Micafungin susceptibility testing was performed using the Etest® (Biomérieux, Marcy 93 l'Etoile, France), according to the manufacturer's instructions. Candida isolates were then 94 centralized in a single center for MIC determination by the EUCAST reference method (13). 95 6 strains (14). For comparison purposes, Etest® MICs were increased to the next higher 97 corresponding EUCAST concentration (15). Resistance was based on EUCAST clinical 98 breakpoints. When clinical breakpoints were not available (i.e. for C. krusei and C. 99 tropicalis), ECOFFs were used to categorize isolates as non-wild-type (16). The same 100 ECOFFs (defined by EUCAST) were used for analyzing results of Etest® as specific ECOFFs 101 have not been determined yet. C.albicans, C. glabrata, and C. parapsilosis isolates were 102 considered susceptible / resistant to micafungin when MICs were ≤0.016 / >0.016 µg/ml, 103 ≤0.03 / >0.03 µg/ml, and ≤0.002 / >2 µg/ml, respectively. C. krusei and C. tropicalis isolates 104 were considered wild-type / non-wild-type to micafungin when MICs were ≤0.25 / >0.25 105 µg/ml and ≤0.06 / >0.06 µg/ml, respectively. MIC results obtained by the two methods were 106 considered to be in essential agreement when they were within ± 2 log 2 dilutions. Agreement 107 at ± 1 log 2 dilution was also calculated. Categorical agreement was defined as the percentage 108 of isolates classified in the same category (i.e. susceptible, intermediate, and resistant or wild-109 type and non-wild-type) by both techniques (15). Discrepancies (very major, major, and 110 minor errors) were defined as described previously (15). 111
Results from antifungal susceptibility testing were available for 933 Candida isolates, 112
including 878 isolates of the six most medically important Candida species and 55 other 113
Candida species. Table 1 shows the micafungin MICs for the 933 isolates determined by the 114 EUCAST reference method. Micafungin MICs for C. parapsilosis isolates (modal MIC of 1 115 µg/ml) were several dilutions higher than for the other common species (modal MIC of 0.015 116 µg/ml for C. albicans, C. tropicalis, and C. glabrata and 0.03 and 0.06 µg/ml for C. kefyr and 117 C. krusei, respectively). MICs for rare species were similar than those of the common species 118 except for C. colliculosa and some isolates of C. guilliermondii and C. famata. According to 119 the current clinical breakpoints (16), the micafungin resistance rate was <2% for C. albicans 120 and C. parapsilosis, and 3.9% for C. glabrata. Based on ECOFFs, the non-wild-type rate was 7 0.7% for C. tropicalis and 0% for C. krusei. The overall essential agreement between 122 EUCAST and Etest® results was high (98.5% at ± 2 log 2 dilutions and 90.2% at ± 1 log 2 123 dilution) ( Figure 1 ) with minor differences between species (Table 2 ). The lowest essential 124 agreement (96.7% at ± 2 log 2 dilutions) was observed for C. parapsilosis. An overall 125 categorical agreement of 98.2% was observed for the 742 isolates belonging to the five 126 species for which clinical breakpoints or ECOFFs are available ( Table 3 ). The highest (100%) 127 and lowest (96.7%) categorical agreements were found for C. krusei and C. glabrata, 128 respectively. Major errors were observed in six cases (three C. albicans, two C. tropicalis, and 129 one C. glabrata) and very major errors in six cases (two C. albicans and four C. glabrata). 130
These 12 discrepancies were observed for strains isolated and tested in eight different centers. 131
The Etest® has been used in several studies for micafungin susceptibility testing of Candida 132 spp. (17-22), but only a few comparative studies with a reference method have been 133 performed (17, (20) (21) (22) . In one of these previous studies, Marcos-Zambrano et al. (21) tested 134 160 yeast isolates with both the Etest® and EUCAST methods and reported an essential 135 agreement of 90.3% at ± 2 log 2 dilutions (85.8% at ± 1 log 2 dilution) and a categorical 136 agreement of >90%. Similarly, in another study, a comparison between Etest® and CLSI 137 methods showed an overall essential agreement of 94.7% and a categorical agreement of 138 97.2% (20) . The ability of the Etest® to detect micafungin resistance, for most of the species, 139 has also been demonstrated previously by testing FKS mutant isolates (17, 21, 22 # C. guilliermondii (9), C. norvegensis (5) , C. inconspicua (5) , C. famata (3), C. pelliculosa 278
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